| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|---|---|---|---|---|---|---|
Revenue: | |||||||
Total revenue | |||||||
19,886 | 13,469 | 911 | 86 | 3,803 | 3,177 | 11,964 | 1,190 |
Operating expenses: | |||||||
Research and development | |||||||
113,820 | 75,531 | 48,524 | 49,253 | 21,221 | 15,068 | 8,685 | 4,597 |
General and administrative | |||||||
17,745 | 15,320 | 11,872 | 9,233 | 7,770 | 6,181 | 3,516 | 2,829 |
Total operating expenses | |||||||
131,565 | 90,851 | 60,396 | 58,486 | 28,991 | 21,249 | 12,201 | 7,426 |
Operating loss | |||||||
-111,679 | -77,382 | -59,485 | -58,400 | -25,188 | -18,072 | -237 | -6,236 |
Other income, net | |||||||
4,490 | 2,980 | 1,156 | 652 | 101 | 126 | -3,756 | -66 |
Loss before benefit from income taxes | |||||||
-107,189 | -74,402 | -58,329 | -57,748 | -25,087 | -17,946 | -3,993 | -6,302 |
Benefit from income taxes | |||||||
-816 | -389 | -204 | -468 | -397 | -201 | -30 | -31 |
Net loss | |||||||
-106,373 | -74,013 | -58,125 | -57,280 | -24,690 | -17,745 | -3,963 | -6,271 |
Basic and Diluted | |||||||
- | - | - | - | - | - | -3,072 | -6,271 |
Net loss per share: | |||||||
Basic and Diluted | |||||||
-2.49 | -2.06 | -1.86 | -2.10 | -1.00 | -0.85 | -0.74 | -1.90 |
Weighted average shares: | |||||||
Basic and Diluted | |||||||
42,669 | 35,892 | 31,202 | 27,279 | 24,620 | 20,965 | 4,133 | 3,299 |
Other comprehensive income (loss), net of tax of $0: | |||||||
Change in unrealized gains (losses) on available-for-sale marketable securities | |||||||
284 | -44 | -73 | 38 | -35 | - | - | - |
Total comprehensive loss | |||||||
-106,089 | -74,057 | -58,198 | -57,242 | -24,725 | -17,745 | -3,072 | - |
License and Milestone Fees [Member] | |||||||
Total revenue | |||||||
19,746 | 13,436 | 530 | - | 1,710 | 302 | 9,637 | 1,190 |
Collaborative Revenue [Member] | |||||||
Total revenue | |||||||
- | - | 313 | - | 2,093 | 2,201 | 2,225 | - |
Clinical Compound Revenue [Member] | |||||||
Total revenue | |||||||
140 | 33 | 68 | 86 | - | 674 | 102 | - |